|
Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer. |
|
|
Speakers' Bureau - Merck Serono; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Geneseeq Technology Inc. |
|
|
Employment - Geneseeq Technology Inc. |
|
|
Employment - Geneseeq Technology Inc. |
|
|
Employment - Nanjing Geneseeq Technology |
|
|
Employment - Nanjing Geneseeq Technology |
|
|
Employment - Geneseeq Technology Inc. |
Leadership - Geneseeq Technology Inc. |
Travel, Accommodations, Expenses - Geneseeq Technology Inc. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |